Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe E. who wrote (4616)	6/29/1998 11:26:00 PM
From: Bhag Karamchandani	Read Replies (1) of 6136

Life cycle for any of these drugs is hard to predict- except that it is increasingly shrinking or appears to be threatened( perhaps as much work on AIDS related therapies as cancer ( unverified comment). I would prefer AGPH to have two legs ( if not three) but one leg is inherently unstable. What would be disappointing is IF AGPH shareholders are being set up for another Thymatiq like disappointment. As an AGPH well wisher I hope I am wrong. I am disappointed that AGPH has not provided additional info on the AG 3340 trials - conducted and in progress.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next